Compare DexCom, Inc. (DXCM) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Rockwell Automation — how do they compare? DexCom, Inc. trades at $77.18 (market cap $28.06B), while Rockwell Automation trades at $466.65 (market cap $51.40B). The key difference: Rockwell Automation is the larger of the two by market cap, and Rockwell Automation pays a 1.2% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | ROK | |
|---|---|---|
Market Cap | $28.06B | $51.40B |
Sector | Health | Industrials |
52-Week High | $89.53 | $495.08 |
52-Week Low | $54.84 | $328.67 |
Enterprise Value | $27.03B | $55.03B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Rockwell Automation (ROK) trades at $461.85, down 1.69% on the day, with a bearish technical signal but strong fundamental earnings beats in recent quarters. The stock shows a high P/E of 47.97 and P/S of 5.92, reflecting premium valuation, while profitability metrics include a 12.45% net income margin and 9.66% ROE. Recent news highlights the company's leadership in industrial automation and AI integration, with positive analyst coverage despite mixed technical indicators.
The outlook for ROK is cautiously optimistic, driven by consistent earnings outperformance and strategic positioning in industrial automation. Key risks include elevated valuation multiples and macroeconomic sensitivity, but institutional buy ratings and a $471.71 consensus price target suggest potential upside. Investors should monitor execution on growth initiatives and competitive pressures in the sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
